Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.
Authors
Yong, KCavet, James
Johnson, P
Morgan, G
Williams, C
Nakashima, D
Akinaga, S
Oakervee, H
Cavenagh, J
Affiliation
UCL Cancer Institute, University College London, Huntley Street, London WC1E 6DDIssue Date
2016-01-12
Metadata
Show full item recordAbstract
KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor.Citation
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. 2016, 114 (1):7-13 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2015.422PubMed ID
26695442Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2015.422
Scopus Count
Collections
Related articles
- A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
- Authors: Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S, Yong K
- Issue date: 2017 Oct 24
- Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
- Authors: Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Bladé J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, Iyer SP
- Issue date: 2015 Jul 1
- New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
- Authors: Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y
- Issue date: 2010 May 15
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.
- Authors: Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, Takamatsu Y, Naoe T, Tobinai K, Munakata W, Yamauchi T, Kageyama A, Yuasa M, Motoyama M, Tsunoda T, Hatake K
- Issue date: 2015 Jul
- Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies.
- Authors: Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM Jr, Jillela A
- Issue date: 2013 Aug